Creo Medical Group plc
("Creo" the
"Company" or the "Group")
Creo Medical receives King's Award for
Enterprise in Innovation
Creo Medical Group plc (AIM: CREO),
the medical device company focused on the emerging field of
minimally invasive surgical endoscopy, announces that it is to
receive a King's Award for Enterprise in Innovation, at an event to
be held at Windsor Castle on 9 July 2024.
Established by Royal Warrant in
1965, The King's Awards for Enterprise is the UK's most prestigious
business awards to recognise and encourage achievements in the
fields of Innovation, International Trade, Sustainable Development
and Promoting Opportunity through social mobility.
During the reception, His Majesty
will meet Creo's Chief Executive Officer, Craig Gulliford, as well
as a diverse group of winners from across the United Kingdom, with
recipients of the award able to use The King's Awards emblem for
the next five years on their products and to promote their
services.
Creo Medical Group plc is an innovative and
growing medical technology company. It has developed CROMA, an
advanced energy electrosurgical platform and a range of novel,
miniaturised devices that are used through the small working
channels of endoscopes, enabling the most minimally invasive
surgery where operations are performed from inside the body. Creo's
Speedboat device harnesses CROMA's cutting and coagulation
capabilities to remove cancerous and pre-cancerous growths and
complex lesions in the bowel, oesophagus and stomach. By providing
a solution that reduces the risks associated with conventional
surgical procedures, Creo's Speedboat allows clinicians to
precisely lift, resect and coagulate tissue with a single device,
removing lesions from within the gastrointestinal tract in one
piece. This means patients can be treated as day cases under mild
sedation instead of more invasive surgery requiring general
anaesthetic and multiple days in hospital.
Creo's products deliver benefits to patients,
reduce waiting lists, free up resources, and significantly lower
hospital costs. NHS Supply Chain recently
confirmed net cash savings of £687k were generated for an NHS Trust
from 130 procedures using Creo's core Speedboat technology.
Creo's technology is patent protected, and its devices are
used daily across dozens of countries and in over 20 NHS
hospitals.
Craig Gulliford, Chief Executive
Officer of Creo Medical, said: "We are
delighted to receive this award from His Majesty The King at a
Royal reception in recognition of our team's outstanding work,
dedication and achievements towards innovation in healthcare. I
would like to put on record my thanks to the whole team in their
daily commitment to improving patient outcomes, cutting waiting
times and saving the NHS money. Innovation has always been at the
heart of Creo, and the increasing adoption of our pioneering
technology by clinicians around the world, reflects the significant
benefits that innovation can bring to both patients and healthcare
systems."
Enquiries:
|
Creo Medical
Group plc
|
www.creomedical.com
|
|
Richard Rees (CFO)
|
+44 (0)1291 606
005
|
|
|
|
|
Cavendish
Capital Markets Limited
|
+44 (0)20 7397
8900
|
|
Stephen Keys / Camilla Hume (NOMAD)
|
|
|
Michael Johnson (Sales)
|
|
|
|
|
|
Deutsche Numis
(Joint Broker)
Freddie Barnfield / Duncan Monteith / Euan
Brown
|
+44 (0)20
7260 1000
|
|
|
|
|
Walbrook
PR
|
Tel: +44
(0)20 7933 8780 or
creo@walbrookpr.com
|
|
Paul McManus / Sam Allen
Phillip Marriage
|
Mob: +44
(0)7980 541 893 / +44 (0)7502 558 258
+44
(0)7867 984 082
|
About Creo
Medical (www.creomedical.com)
Creo Medical is a medical device company
focused on the development and commercialisation of minimally
invasive electrosurgical devices, bringing advanced energy to
endoscopy.
The Company's vision is to improve patient
outcomes through the development and commercialisation of a suite
of electrosurgical medical devices, each enabled by CROMA, powered
by Kamaptive. The Group has developed the CROMA powered by
Kamaptive full-spectrum adaptive technology to optimise surgical
capability and patient outcomes. Kamaptive is a seamless, intuitive
integration of multi-modal energy sources, optimised to dynamically
adapt to patient tissue during procedures such as resection,
dissection, coagulation and ablation of tissue. Kamaptive
technology provides clinicians with increased flexibility,
precision and controlled surgical solutions. CROMA currently
delivers bipolar radiofrequency ("RF") energy for precise localised
cutting and focused high frequency microwave ("MW") energy for
controlled coagulation and ablation via a single accessory port.
This technology, combined with the Group's range of patented
electrosurgical devices, is designed to provide clinicians with
flexible, accurate and controlled clinical solutions. The Directors
believe the Company's technology can impact the landscape of
surgery and endoscopy by providing a safer, less-invasive and more
cost-efficient option for procedures.
About The
King's Award
The King's Awards for Enterprise are the most
prestigious awards for UK businesses, previously known as The
Queen's Awards for Enterprise. The Awards recognise and celebrate
business excellence in innovation, international trade, sustainable
development and promoting opportunity (through social
mobility).
Awardees receive a Grant of Appointment and a
trophy presented by one of HM Lord-Lieutenants, and are able to
display the Award Emblem for up five years. They also have access
to a thriving alumni network of previous award winners.
Recipients of the Award often state that their
achievement has opened new doors for them in terms of securing new
contracts, venturing into new markets, and further developing their
business.
https://www.gov.uk/kings-awards-for-enterprise